#METABOLOMICS WORKBENCH michaelsa93_20170830_131510_mwtab.txt DATATRACK_ID:1230 STUDY_ID:ST000873 ANALYSIS_ID:AN001479 PROJECT_ID:PR000604
VERSION             	1
CREATED_ON             	January 3, 2018, 4:03 pm
#PROJECT
PR:PROJECT_TITLE                 	Maternal Hypoxemia and oxidative stress in the fetus, newborn, and adult.
PR:PROJECT_SUMMARY               	Gestational hypoxia presents a significant stress to an unborn fetus that can
PR:PROJECT_SUMMARY               	lead to significant complications related to fetal growth restriction and
PR:PROJECT_SUMMARY               	resulting in diseases in the newborn as well as those manifesting later in life.
PR:PROJECT_SUMMARY               	Recent evidence indicates that inflammation and oxidative stress are
PR:PROJECT_SUMMARY               	contributing factors to hypoxia-related diseases. The Center for Perinatal
PR:PROJECT_SUMMARY               	Biology at Loma Linda University has studied gestational chronic hypoxia in a
PR:PROJECT_SUMMARY               	sheep model for over 20 years to study dysfunction of vascular and nonvascular
PR:PROJECT_SUMMARY               	tissues derived from mothers, fetuses and offspring. In this project we are
PR:PROJECT_SUMMARY               	attempting to use metabolomics to assess metabolic dysregulation in vascular
PR:PROJECT_SUMMARY               	tissues along with markers of oxidative stress and inflammation in the mother
PR:PROJECT_SUMMARY               	and offspring to determine the extent of dysregulation due to chronic hypoxia.
PR:PROJECT_SUMMARY               	Untargeted metabolomics analysis focused on sheep plasma and arteries from the
PR:PROJECT_SUMMARY               	lung, resistance arteries in the brain, uterine arteries, and cultured human
PR:PROJECT_SUMMARY               	myocytes will be used to explore markers of glucose and lipid metabolism
PR:PROJECT_SUMMARY               	disruption. Targeted analyses of oxylipins and endocannabinoids will be used on
PR:PROJECT_SUMMARY               	the same samples to explore markers of oxidative stress and inflammation, which
PR:PROJECT_SUMMARY               	should be increased during hypoxia. This study should delineate pathways and
PR:PROJECT_SUMMARY               	biomarkers that help explain how hypoxia leads to the development of neonatal as
PR:PROJECT_SUMMARY               	well as adult-onset diseases associated with chronic hypoxia that are
PR:PROJECT_SUMMARY               	inter-related with fetal growth restriction.
PR:INSTITUTE                     	University of California, Davis
PR:DEPARTMENT                    	Genome and Biomedical Sciences Facility
PR:LABORATORY                    	WCMC Metabolomics Core
PR:LAST_NAME                     	Fiehn
PR:FIRST_NAME                    	Oliver
PR:ADDRESS                       	1315 Genome and Biomedical Sciences Facility, 451 Health Sciences Drive, Davis,
PR:ADDRESS                       	CA 95616
PR:EMAIL                         	ofiehn@ucdavis.edu
PR:PHONE                         	(530) 754-8258
PR:FUNDING_SOURCE                	NIH U24DK097154
#STUDY
ST:STUDY_TITLE                   	Maternal Hypoxemia and oxidative stress in the fetus, newborn, and adult.
ST:STUDY_TITLE                   	exercise training for peripheral artery disease (part II)
ST:STUDY_TYPE                    	Disease model
ST:STUDY_SUMMARY                 	Gestational hypoxia presents a significant stress to an unborn fetus that can
ST:STUDY_SUMMARY                 	lead to significant complications related to fetal growth restriction and
ST:STUDY_SUMMARY                 	resulting in diseases in the newborn as well as those manifesting later in life.
ST:STUDY_SUMMARY                 	Recent evidence indicates that inflammation and oxidative stress are
ST:STUDY_SUMMARY                 	contributing factors to hypoxia-related diseases. The Center for Perinatal
ST:STUDY_SUMMARY                 	Biology at Loma Linda University has studied gestational chronic hypoxia in a
ST:STUDY_SUMMARY                 	sheep model for over 20 years to study dysfunction of vascular and nonvascular
ST:STUDY_SUMMARY                 	tissues derived from mothers, fetuses and offspring. In this project we are
ST:STUDY_SUMMARY                 	attempting to use metabolomics to assess metabolic dysregulation in vascular
ST:STUDY_SUMMARY                 	tissues along with markers of oxidative stress and inflammation in the mother
ST:STUDY_SUMMARY                 	and offspring to determine the extent of dysregulation due to chronic hypoxia.
ST:STUDY_SUMMARY                 	Untargeted metabolomics analysis focused on sheep plasma and arteries from the
ST:STUDY_SUMMARY                 	lung, resistance arteries in the brain, uterine arteries, and cultured human
ST:STUDY_SUMMARY                 	myocytes will be used to explore markers of glucose and lipid metabolism
ST:STUDY_SUMMARY                 	disruption. Targeted analyses of oxylipins and endocannabinoids will be used on
ST:STUDY_SUMMARY                 	the same samples to explore markers of oxidative stress and inflammation, which
ST:STUDY_SUMMARY                 	should be increased during hypoxia. This study should delineate pathways and
ST:STUDY_SUMMARY                 	biomarkers that help explain how hypoxia leads to the development of neonatal as
ST:STUDY_SUMMARY                 	well as adult-onset diseases associated with chronic hypoxia that are
ST:STUDY_SUMMARY                 	inter-related with fetal growth restriction.
ST:INSTITUTE                     	USDA
ST:DEPARTMENT                    	Obesity and metabolism research unit
ST:LABORATORY                    	Newman's Lab
ST:LAST_NAME                     	Newman
ST:FIRST_NAME                    	John
ST:ADDRESS                       	430 West Health Sciences Dr. Davis, Ca, 95616
ST:EMAIL                         	John.Newman@ars.usda.gov
ST:PHONE                         	(530) 752-1009
#SUBJECT
SU:SUBJECT_TYPE                  	Sheep
SU:SUBJECT_SPECIES               	Ovis aries
SU:TAXONOMY_ID                   	9940
SU:GENDER                        	Both
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	S41	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S42	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S43	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S44	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S45	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S46	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S54	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S55	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S56	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S57	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S58	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S47	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S48	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S49	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S50	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S51	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S52	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S53	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S59	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S60	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S61	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S62	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S63	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S64	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S36	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S37	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S38	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S39	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S40	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S31	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S32	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S33	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S34	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S35	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S26	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S27	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S28	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S29	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S30	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S21	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S23	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S24	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S25	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S107	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S89	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S91	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S93	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S104	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S105	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S106	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S71	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S72	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S95	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S79	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S80	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S81	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S82	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S101	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S102	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S83	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S84	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S85	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S87	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S88	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S103	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	
SUBJECT_SAMPLE_FACTORS           	-	S74	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S96	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S97	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:New Born	
SUBJECT_SAMPLE_FACTORS           	-	S65	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S66	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S67	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S68	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S98	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S99	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S100	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S1	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S2	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S3	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S4	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S5	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S6	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S7	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S8	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S9	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S10	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S11	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S12	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S13	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S14	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S15	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S16	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S17	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S18	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S19	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	
SUBJECT_SAMPLE_FACTORS           	-	S20	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	
#COLLECTION
CO:COLLECTION_SUMMARY            	Part of the routinely flash frozen samples from the Loma Linda University School
CO:COLLECTION_SUMMARY            	of Medicine, Center for Perinatal Biology.
CO:SAMPLE_TYPE                   	Tissue
CO:TISSUE_CELL_IDENTIFICATION    	Adipose tissue, Carotid, pulmonary arteries, uterine arteries
#TREATMENT
TR:TREATMENT_SUMMARY             	To induce chronic hypoxia, pregnant and non-pregnant ewes were transported to
TR:TREATMENT_SUMMARY             	the White Mountain Research Station that is owned and operated by the University
TR:TREATMENT_SUMMARY             	of California. Animals were housed at the Barcroft Research Station (3800 m) for
TR:TREATMENT_SUMMARY             	100+ days prior to having the pregnant or non-pregnant ewes or 2 week old
TR:TREATMENT_SUMMARY             	newborn lambs transported back to Loma Linda for study.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	After sample randomization, weighed tissue (around 10mg for adipose and 50mg for
SP:SAMPLEPREP_SUMMARY            	arteries) in 2 mL polypropylene Eppendorf tube was enriched with deuterated
SP:SAMPLEPREP_SUMMARY            	surrogates in 20µL methanol (Tables S1 and S2 from Agrawal, K., L.A. Hassoun,
SP:SAMPLEPREP_SUMMARY            	N. Foolad, T.L. Pedersen, R.K. Sivamani, J.W. Newman. 2017. Sweat lipid mediator
SP:SAMPLEPREP_SUMMARY            	profiling: a non-invasive approach for cutaneous research. J. Lipid Res.
SP:SAMPLEPREP_SUMMARY            	58:188–195 [EPub: Nov 7, 2016]. doi: 10.1194/jlr.M071738) and 5 μl of
SP:SAMPLEPREP_SUMMARY            	BHT/EDTA in 1:1 methanol/water (v/v). A total of 400 μl 1-cyclohexyl uredio,
SP:SAMPLEPREP_SUMMARY            	3-dodecanoic acid / 1-phenyl ureido, 3-hexanoic acid (CUDA / PUHA) in 1:1
SP:SAMPLEPREP_SUMMARY            	methanol/acetonitrile (v/v) was added, the sample ground with 3mm stainless
SP:SAMPLEPREP_SUMMARY            	steel beads (two for adipose tissue and 3 for blood vessel tissue) and agitation
SP:SAMPLEPREP_SUMMARY            	for 6 min at 1500RPM. Protein precipitate and debris were removed by
SP:SAMPLEPREP_SUMMARY            	centrifugation (10 min, 10,000 RCF, 6 °C). The supernatant was filtered by
SP:SAMPLEPREP_SUMMARY            	centrifugation through 1 µm PVDF membranes (Millipore, Billerica, MA) at 6 °C
SP:SAMPLEPREP_SUMMARY            	and 4,500 RCF for 3 min. The filtrate was stored in glass vials at -20 °C until
SP:SAMPLEPREP_SUMMARY            	UPLC-MS/MS analysis.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	Aquity C18 BEH 1.7µm 100mm x 2.1mm column
CH:FLOW_GRADIENT                 	See protocol/methods file
CH:FLOW_RATE                     	0.25 mL/min
CH:COLUMN_TEMPERATURE            	60 °C
CH:SOLVENT_A                     	0.1% acetic acid
CH:SOLVENT_B                     	90% ACN / 10% IPA
CH:INTERNAL_STANDARD             	See protocol/methods file
CH:RETENTION_TIME                	See protocol/methods file
CH:SAMPLE_INJECTION              	5 µL
CH:ANALYTICAL_TIME               	20 min
CH:WEAK_WASH_SOLVENT_NAME        	20% methanol, 10% isopropanol
CH:WEAK_WASH_VOLUME              	600 µL
CH:STRONG_WASH_SOLVENT_NAME      	50:50 Acetonitrile:Methanol
CH:STRONG_WASH_VOLUME            	600 µL
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	ABI Sciex 6500 QTrap
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	Concentration (nM)
MS_METABOLITE_DATA_START
Samples	S41	S42	S43	S44	S45	S46	S54	S55	S56	S57	S58	S47	S48	S49	S50	S51	S52	S53	S59	S60	S61	S62	S63	S64	S36	S37	S38	S39	S40	S31	S32	S33	S34	S35	S26	S27	S28	S29	S30	S21	S23	S24	S25	S107	S89	S91	S93	S104	S105	S106	S71	S72	S95	S79	S80	S81	S82	S101	S102	S83	S84	S85	S87	S88	S103	S74	S96	S97	S65	S66	S67	S68	S98	S99	S100	S1	S2	S3	S4	S5	S6	S7	S8	S9	S10	S11	S12	S13	S14	S15	S16	S17	S18	S19	S20
Factors	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Normoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Adipose | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Carotid | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:New Born	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:New Born	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:New Born	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Fetal	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:New Born	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Pulmonary Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Normoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult non-pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant	Tissue type:Uterine Arteries | Treatment group:Hypoxic | Life stage:Adult pregnant
9-Nitrooleate	13.2	2.57	7.18		2.21	3.02	5.78		2.96	2.62		10.6		4.58			5.67	4.93		3.58		2.46		3.66	1.47	0.322	2.41	4.56	2.34	1.27		5.26	6.87		2.19	2.2		1.39	5.99	1.33		2.06	3.61	2.98	2.59		3.07		1.87	2.32	8.1	5.43	8.48	2.51	6.38		0.985	1.55		2.14	0.848	15.8	1.62			2.85		0.895				2.91	1.01	4.17	3.46		5.29	2.24	7.28	1.73		10.7					3.6			3.69		2.57	5.03	1.5	2.85
10-Nitrolinoleate	7.52	17.1	4.21	3	1.49	9.22		4.96	5.73	3.91	6.78		0.66	1.28	1.44	1.71	5.14	3.63	1.48	0.92	2.37	2.1	0.394	4.06	1.8	0.57	0.432	3.98	2.83	0.734	1.19		18	5.79	0.477	1.72		0.494	0.000268	0.544	0.41	2.05	2.18	1.09	1.25	0.411	0.304	3.27	2.58	0.537	6.22	0.979		4.25		2.54		0.855	2.78	0.843		18.7	1.28	0.28	0.38	3.22	3.93	14.1	1.55	1.08	0.977			0.627	2.74	2.28	1.09	0.512	4.05	0.332	1.35	12.9	2.88	3.82	2.35	2.49	1.47		1.38	3.55	2.11	2.75	1.06	0.49	1.35
OEA	762	63.4	139	257	82.6	171	81.6	213	288	398	261	184	86.3	57.6	57.9	72.5	54.8	111	24.8	45.2	137	21.9	20.8	13.5	4.42	30.5	5.44	3.58	5.3	31.1	16.9	2.99	3.21	2.33	3.78	7.5	3.44	7.76	5.14	3.17	1.56	3.93	2.47	14.3	7.57	4.79	3.09	18.1	9.48	16.7	33.2	42.6	119	2.97	10.5	7.46	4.85	15	25.7	6.1	10.6	6.03	6.44	8.64	29.9	18.7	799	1460	3.82	3.66	4.57	5.69	25	12.9	22.5	2.56	3.64	3.97	3.92	2.38	2.56	1.96	2.24	1	2.78	1.52	1.04	3.63	2.41	3.7	0.587	1.14	2.69	2.22	6.2
LEA	9.3	2.55	5.69	11	1.02	7.79	56.4	35.1	136	101	36.8	9.82	3.91	2.04	1.48	1.69	3.21	7.41	3.88	27.8	57	8.48	5.29	4.2	0.208	0.292	0.31	0.446	0.324	9	3.55	0.535	0.498	0.409	0.0697	0.192	0.0869	0.137	0.164	0.221	0.465	0.417	0.527	4.99	0.0518	0.0527	0.0291	0.241	0.382	0.33	15	12.7	39.2	0.207	0.935	0.843	0.944	2.85	2.15	0.114	0.26	0.21	0.0777	0.116	0.77	6.79	378	600	0.862	0.705	1.33	1.39	5.36	3.57	6.68	0.523	0.435	0.472	0.331	0.454	0.585	0.555	0.514	0.872	0.973	0.394	0.593	0.686	0.412	0.917	0.649	1.14	0.956	1.1	1.59
aLEA	0.93	0.242	0.288	1.12	0.0245	0.732	12.6	8.23	16	18.6	5.58	0.847		0.107	0.116		0.152	0.239	0.387	1.2	3.36	0.864	0.961	0.553	0.0365	0.00757	0.00725	0.0341	0.0332	0.994	0.348	0.0385	0.142	0.0162		0.00305	0.00189	0.0175	0.00184	0.00743	0.0266	0.0295	0.0336	0.226	0.0106			0.00732	0.038	0.00965	1.9	1.63	5.34	0.0565	0.113	0.0982	0.132	0.596	0.556	0.00775	0.00253	0.0375				1.17	9.54	64	0.0217	0.0363	0.0365	0.0601	0.318	0.153	0.313	0.0825	0.0538	0.0395	0.0557	0.0625	0.102	0.0494	0.0614	0.0723	0.0732	0.00741	0.0128	0.0137	0.0201	0.0367	0.0373	0.0703	0.0432	0.0844	0.107
Dihomo GLA EA	5.41	0.824	0.513	3.34	0.384	2.84	1.49	2.69	2.03	1.08	0.72	1.82	0.705	1.07	0.583		0.662	2.29	0.698	0.686	2.06	0.597	0.159	0.197	0.0396		0.000381	0.0149	0.0252	2.39	1.4	0.114	0.114	0.101	0.0251	0.0884	0.00288			0.0701	0.119	0.386	0.123	1.01			0.0265	0.0415	0.165	0.0383	1.85	2.1	4.61	0.142	0.199	0.155	0.0286	0.397	0.733	0.0266		0.0864	0.0414		0.0995	1.19	55.8	108	0.0658	0.215	0.0695	0.0557	0.365	0.161	0.329	0.0511	0.0246	0.118	0.0162	0.0276	0.0377	0.0559		0.111	0.207	0.062	0.0826	0.0311	0.0241	0.12	0.0737	0.114	0.0723	0.241	0.159
AEA	104	24.7	45.2	106	14.7	73.4	11.5	7.66	13.9	13.4	4.15	85.3	40.5	23.6	18.2	23.8	27.2	52.2	7.16	7.64	16.1	3.35	4.09	1.85	0.639	0.786	1.06	0.354	0.611	13.1	5.05	0.459	0.448	0.0796	0.313	0.857	0.278	0.884	0.416	0.131	0.24	0.21	0.421	2.85	0.507	0.25	0.153	0.677	0.797	1.34	24.8	22.3	51.2	0.285	0.696	0.625	0.243	0.462	0.632	0.401	0.6	0.445	0.513	0.579	1.83	12.9	632	623	0.328	0.332	0.328	0.241	1.63	1.01	0.743	0.538	0.74	0.794	0.352	0.533	0.374	0.4	0.259	0.496	0.698	0.586	0.8	0.755	0.75	0.681	0.474	0.539	0.717	0.798	1.27
DEA	1.38	0.27	0.455	0.753	0.517	0.548	0.235	0.406	0.43	0.45	0.139	0.885	0.945	1.95	0.68	0.635	1.01	1.19	0.478	0.621	0.818	0.283	0.267	0.527	0.364	1.07	0.722	0.762	1.75	5.16	0.87	0.143	0.73		0.255	0.646	0.263	0.402	0.598	0.311	0.389	0.0764	0.954	0.873	0.691	0.189	0.415	0.741	0.603	0.758	2.54	1.98	3.93	0.563	0.305	0.555	0.123	1.88	1.32	1.08	0.812	1.15	0.338	0.613	1.51	0.761	43.5	29.3	0.316	0.149	0.799	0.218	2.07	1.19	1.08	0.128	0.129	0.0754	0.0963	0.0228	0.0859	0.155	0.172	0.49	0.178	0.162	0.158	0.0866	0.192	0.207	0.0486	0.725	0.192	1.62	0.683
DHEA	54	13.2	21.5	44	13.9	22.4	16.1	11.9	12.1	12.4	7.55	29.8	15.8	14.3	12.9	11.7	15	18	4.6	3.44	8.06	4.82	4.71	5.81	0.529	2.38	0.533	0.353	0.52	7.95	1.25	0.142	0.382	0.0967	0.245	0.263	0.137	0.233	0.155	0.173	0.2	0.164	0.248	0.98	0.808	0.227	0.562	1.42	1.42	2.36	7.4	5.97	14.1	0.229	0.314	0.256	0.24	0.736	0.359	0.311	0.197	0.317	0.262	0.401	0.48	4.44	42	55.2	0.0938	0.277	0.135	0.194	0.625	0.535	0.243	0.32	0.278	0.261	0.208	0.163	0.231	0.349	0.396	0.518	0.463	0.162	0.218	0.386	0.212	0.138	0.169	0.455	0.278	0.477	0.951
NO-Gly	6.77	10.7	25.5	34.2	13.5	19.9	40.2	8.71	57.9	39.4	8.31	25	7.75		8.36	9.07	10	10.5	4.75	31	23.6	16.6	17.2	13.3									0.902							0.0399										0.0286										0.0171	0.0137								0.024			0.0171		0.0643		1.99	0.816	1.06	0.973	0.621	1.53	2.9	0.82	0.901	1.57	0.76	0.68	0.792	0.968	1.33	0.572	0.721	0.578	0.374	0.441
NA-Gly	0.541	2.67	1.13	4.07	0.568	0.681	6.98	3.07	3.9	1.08	0.978	3.63	1.2	0.884	0.894	0.4	0.639	1.77	2.71	2.63	3.96	1.1	0.386	2.12	0.743	0.805	1.75	2.48	1.26	108	35.4	0.326	2.37	0.6	1.23	2.8	0.535	2.46	0.505	0.654	1.05	0.717	2.57	13.6	0.899	0.255	0.107	0.355	0.762	1.21	22.7	26	37.7	0.391	0.824	1.2	0.162	1.34	1.43	0.267	0.316	1.91	0.349	0.263	1.6	24.8	220	796	0.246	0.564	0.313	0.499	3.29	1.81	1.16	0.489	0.0846	0.692	0.254	0.00697	1.05	1.98	0.992	1.72	1.25	0.348	0.56	0.504	0.611	1.03	0.732	1.04	0.679	1.08	0.664
OG	258000	23200	65300	85800	40500	38300	28800	121000	115000	139000	133000	75600	15800	52100	36800	59900	38500	118000	8040	24900	12600	39000	38500	11100	1990	20200	9300	16400	8640	1610	1950	3780	2200	2970	4300	4460	2260	1830	3560	1620	3010	1620	2600	1110	6260	4780	13800	1940	1750	1550	4840	5370	7800	13300	12800	10100	4590	1900	9690	10100	3580	10200	3530	8030	4270	3950	44600	54900	1870	2360	6560	5190	3090	1750	1640	1210	1570	3470	1430	454	3800	9350	12100	9600	4690	3830	1530	1740	2760	3730	6030	5570	2650	7760	3510
LG	128	215	1340	2510	556	530	12100	1330	17000	18000	5380	1150	149	273	277	780	360	2320	1250	8080	3190	9890	13600	3310		222		38.5		327	446	284	1430	114	0.088	18.7	11.3	7.75	14.1	385	368	430	536	236	23.1	6.25	19			4.87	1220	1380	1370	226	686	676	505	116	27.6	52.4	25.5	293	35.1	76.1	7.9	1090	1450	12800	274	403	349	457	314	222	338	419	671	712	633	305	589	1510	914	760	925	2940	1060	1350	1140	1200	4340	2340	1270	612	666
AG	439	289	672	804	713	455	517	286	718	556	734	891	652	836	498	895	820	1490	172	256	298	364	697	279	437	2330	2260	2630	1290	618	1920	2660	2040	3260	1210	1940	1460	1040	1390	1630	4940	2520	4870	789	1360	1520	1630	192	164	175	1580	1760	1120	6350	3130	6090	2910	837	745	3300	1040	2130	1090	1840	612	1110	3250	12500	2020	1040	8070	4830	979	735	947	3810	2870	6550	2560	1300	4110	9980	7020	8240	6810	8090	4570	5260	8500	6910	5640	9230	3190	9770	3290
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	PubChem CID	KEGG	Other_ID	Parent Lipid	Class	HMDB ID	InChIKey
9-Nitrooleate	53412232		53412232	C18:1n9	Nitrolipid		CQOAKBVRRVHWKV-UHFFFAOYSA-M
10-Nitrolinoleate	5282259		5282259	C18:2n6	Nitrolipid		LELVHAQTWXTCLY-XYWKCAQWSA-N
OEA	5283454		5283454	C18:1n9	Ethanolamide	HMDB02088	BOWVQLFMWHZBEF-KTKRTIGZSA-N
LEA	5283446		5283446	C18:2n6	Ethanolamide	HMDB12252	KQXDGUVSAAQARU-HZJYTTRNSA-N
aLEA	5283449		5283449	C18:3n3	Ethanolamide	HMDB13624	HBJXRRXWHSHZPU-PDBXOOCHSA-N
Dihomo GLA EA	5282272	C13828	5282272	C20:3n6	Ethanolamide	HMDB13625	ULQWKETUACYZLI-QNEBEIHSSA-N
AEA	5281969	C11695	5281969	C20:4n6	Ethanolamide	HMDB04080	LGEQQWMQCRIYKG-DOFZRALJSA-N
DEA	5282273	C13829	5282273	C22:4n6	Ethanolamide	HMDB13626	FMVHVRYFQIXOAF-DOFZRALJSA-N
DHEA	53245830		53245830	C22:6n3	Ethanolamide	HMDB13627	CXWASNUDKUTFPQ-KUBAVDMBSA-N
NO-Gly	6436908		6436908	C18:1n9	N-Acyl Glycine	HMDB13631	HPFXACZRFJDURI-KTKRTIGZSA-N
NA-Gly	5283389		5283389	20:4n6	N-Acyl Glycine	HMDB05096	YLEARPUNMCCKMP-DOFZRALJSA-N
OG	5319879		12178130 & 5319879	C18:1n9	1-Acyl Glycerol & 2-Acyl Glycerol	HMDB11567 & HMDB11537	RZRNAYUHWVFMIP-QJRAZLAKSA-N & UPWGQKDVAURUGE-KTKRTIGZSA-N
LG	5365676		6436630 & 5365676	C18:2n6	1-Acyl Glycerol & 2-Acyl Glycerol	HMDB11568 & HMDB11538	WECGLUPZRHILCT-GSNKCQISSA-N & IEPGNWMPIFDNSD-HZJYTTRNSA-N
AG	5282280		16019980 & 5282280	C20:4n6	1-Acyl Glycerol & 2-Acyl Glycerol	HMDB11578 & HMDB04666	DCPCOKIYJYGMDN-HUDVFFLJSA-N & RCRCTBLIHCHWDZ-DOFZRALJSA-N
METABOLITES_END
#END